Barosense

About Barosense

BaroSense Inc. operates as a medical device company focused on creating less invasive solutions for obesity treatment. Founded in 2001 by Richard Stack and William Starling, the company is headquartered in Redwood City, California. The firm has concentrated its efforts on developing restrictive oral and gastric implants designed to induce a feeling of satiety. This approach serves patients who are seeking alternatives to extensive and irreversible weight-loss surgeries.

The company's product development was guided by key surgical principles: that stomach restriction is effective for weight reduction and that durable stomach modification can be achieved through serosal to serosal apposition. This led to the creation of products like the investigational Trans-Oral Endoscopic Restrictive Implant System. This system involves a procedure performed through the mouth to place a soft silicone device in the stomach, which is intended to make a person feel full after a small meal. Another key instrument was the Articulating Circular Endoscopic (ACE) Stapler, an investigational tool for endoluminal trans-oral tissue approximation in the gastrointestinal tract. The FDA granted a 510(k) premarket notification for the BAROSENSE ENDOGASTRIC TUBE AND INTRODUCER BOUGIE in September 2012.

Throughout its history, BaroSense has secured significant financial backing, raising a total of $45.7M to $61.1M over several funding rounds from at least nine institutional investors, including Inovia Capital, Pappas Capital, Frazier Healthcare Partners, and Delphi Ventures. The company's first funding round occurred in September 2002, with its latest announced Series D round in late 2009. According to one of its investors, Pappas Capital, BaroSense's assets were sold in 2013, and other sources describe the company as having been 'acqui-hired'.